Novo Nordisk (NVO) stock news

Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?

These stocks have been going in different directions over the past year, but that trend may not necessarily continue.

The FDA Ordered GLP-1 Vision-Loss Warnings For Some Products. Shares of Eli Lilly and Novo Nordisk Were Unfazed.

The updated labeling covers Mounjaro, Zepbound, Ozempic and Wegovy.

Novo-backed Windward Bio targets $1 billion valuation in US IPO

Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway?

Novo got a much-needed boost from its latest earnings report.

Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should Know

The Wegovy maker raised its outlook again and the stock jumped. But its CEO refused to forecast next year, and handed investors six clues instead.

European shares jump over 1% after Democrats sweep US Congress, Novo Nordisk surges

European shares jump to 2-month highs following U.S. midterms; Novo surges

Stocks making the biggest moves premarket: Trump Media, Tesla, CoreWeave, Novo Nordisk and more

These are the stocks posting the largest moves in the premarket.

Novo shares jump as Wegovy pill sales impress, drugmaker hikes outlook

Novo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates

Beleaguered Novo offers relief to investors, thanks to Wegovy pill

Novo Nordisk stock jumped higher on Wednesday as the Danish drugmaker lifted its guidance on strong uptake of its weight-loss drug pill that has been launched this year.

Why is Novo Nordisk stock surging today?

Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?

Novo Nordisk is shifting its business model, with 2026 likely to represent an inflection point.

Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.

Court rejects Novo bid to block Lilly obesity drug ads

Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.

US judge won’t block Eli Lilly ads for weight-loss drugs, rules against Novo Nordisk

Novo Nordisk A/S Reports Share Repurchase Transactions Under DKK 15 billion Programme

Novo Nordisk A/S has announced transactions under its share repurchase programme. On 6 May 2026, the company initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and…

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?

Novo is facing some headwinds, but it has a plan to overcome them.

Novo Nordisk and Eli Lilly Just Got Some Fantastic News

A new government-funded study found that GLP-1 drugs slow the aging process in mice.